Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06255496 · ClinicalTrials.gov registry record
QStat Cartridge in Obstetric Patients
A clinical trial of Postpartum Hemorrhage and Blood Loss Massive, sponsored by HemoSonics.
- Completed
- Registry status
- 296
- Enrollment target
- 6
- Study locations
NCT06255496: Completed study of Postpartum Hemorrhage and Blood Loss Massive, sponsored by HemoSonics.
NCT06255496 is a study of Postpartum Hemorrhage and Blood Loss Massive that has completed, run by HemoSonics. The registered enrollment target is 296 participants, below the 765-participant average among 19 other Postpartum Hemorrhage trials with a reported enrollment target (61% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06255496, a study of Postpartum Hemorrhage and Blood Loss Massive, has completed, sponsored by HemoSonics.
- COMPLETED
- Registry status
- 296 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will assess the performance of the Quantra System with the QStat Cartridge versus standard of care coagulation testing in pregnant women at risk of bleeding at delivery.
Primary Outcome
Coagulation function assessed by Quantra Clot Time (CT, sec) and activated partial thromboplastin (aPTT, sec) test
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Quantra Hemostasis Analyzer with the QStat Cartridge
Study Locations (6)
New York
- University of Rochester Medical Center - Rochester
Ohio
- Ohio State University Wexner Medical Center - Columbus
Oklahoma
- University of Oklahoma Medical Center - Oklahoma City
Pennsylvania
- Magee Womens Hospital - Pittsburgh
Texas
- Parkland Health - Dallas
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2024-05-09 |
| Est. Completion | 2025-10-30 |
What the finished NCT06255496 record still lists
NCT06255496 is an observational study that tracks outcomes without assigning an intervention. The registered 296 participants enrollment target is mid-sized for trials with a published cap, below the 765-participant average among 19 other Postpartum Hemorrhage trials with a reported enrollment target (61% lower).
The record links to 2 conditions, with Postpartum Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which Quantra Hemostasis Analyzer with the QStat Cartridge is the first listed.
NCT06255496 lists 6 locations in 6 states (New York, Ohio, Oklahoma).
Frequently Asked Questions
What is clinical trial NCT06255496 about?
NCT06255496 is a clinical study titled "QStat Cartridge in Obstetric Patients". This study will assess the performance of the Quantra System with the QStat Cartridge versus standard of care coagulation testing in pregnant women at risk of bleeding at delivery.
What is the current status of trial NCT06255496?
This trial is currently completed. The enrollment target is 296 participants. The study started on 2024-05-09. Estimated completion is 2025-10-30.
What conditions does trial NCT06255496 study?
This clinical trial studies the following conditions: Postpartum Hemorrhage, Blood Loss Massive.
What interventions are being tested in trial NCT06255496?
The interventions under investigation include: Quantra Hemostasis Analyzer with the QStat Cartridge (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06255496?
This trial is sponsored by HemoSonics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06255496 being conducted?
This trial has 6 study locations across New York, Ohio, Oklahoma, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postpartum Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06255496's enrollment target sits among peer trials
296 4th of 19 higher than 16 of 19 other Postpartum Hemorrhage trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postpartum Hemorrhage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Effectiveness of the KOKO Device to Treat Primary Abnormal Postpartum Uterine Bleeding or Hemorrhage
RECRUITING · NA
-
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
RECRUITING · Phase 3
-
Oxytocin Pharmacokinetics and Pharmacodynamics
RECRUITING · Phase 2
-
A Pragmatic Randomized Controlled Trial to Predict Postpartum Hemorrhage
RECRUITING · NA
-
Prevention of Postpartum Hemorrhage With Tranexamic Acid
RECRUITING · Phase 2
-
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05563792 · 296 participants · NA
Options for Pain Management Using Nonpharmacological Strategies
- NCT06828445 · 296 participants · Phase 1
Increasing Affordable Fruits and Vegetables for Families With Food Insecurity
- NCT06920563 · 296 participants · NA
Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI